{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:53:43Z","timestamp":1769846023718,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008786","name":"University of Southern California Keck School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.urolonc.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T08:18:30Z","timestamp":1669105110000},"page":"107.e9-107.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-2491","authenticated-orcid":false,"given":"Antoin","family":"Douglawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ghoreifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyedeh-Sanam","family":"Ladi-Seyedian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhannad","family":"Alsyouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gus","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Bhanvadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman","family":"Djaladat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Schuckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-9598","authenticated-orcid":false,"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.09.013_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.013_bib0002","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2022.09.013_bib0003","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.09.013_bib0004","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.013_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.09.013_bib0006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.013_bib0007","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.juro.2006.03.038","article-title":"Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era","volume":"176","author":"Hautmann","year":"2006","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.013_bib0008","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.013_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-15-1208","article-title":"Pathological T0 following cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: a network meta-analysis","volume":"22","author":"Kim","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2022.09.013_bib0010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.013_bib0011","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.juro.2010.04.081","article-title":"Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients","volume":"184","author":"Tilki","year":"2010","journal-title":"J Urol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2022.09.013_bib0012","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257","volume":"39","author":"Glasky","year":"2021","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.013_bib0013","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.09.013_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.urolonc.2022.09.013_bib0015","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00345-016-1801-y","article-title":"The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy","volume":"34","author":"Parker","year":"2016","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.013_bib0016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2011.05.050","article-title":"Bladder cancer research consortium. Stage pT0 after radical cystectomy: are all patients equal?","volume":"60","author":"Chromecki","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.013_bib0017","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.013_bib0018","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.eururo.2007.03.086","article-title":"P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors","volume":"52","author":"Kassouf","year":"2007","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:43Z","timestamp":1761042343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1078143922003477"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: A 20-year experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}